Sr One Capital Management, LLC: insider trades.
Sr One Capital Management, LLC reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($27.2M) and 0 sales, across 1 company.
- Transactions
- 9
- Purchases (P)
- 3
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- SR ONE CAPITAL MANAGEMENT, LLC
Companies
| Company | Relationship | Transactions |
|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | TenPercentOwner | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,538,691 | — | 1,538,691 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 512,897 | — | 4,961,501 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,113,666 | — | 4,448,604 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 3,334,938 | — | 3,334,938 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 414,814 | $17 | 1,953,505 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,667,468 | — | 1,667,468 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 169,001 | — | 1,836,469 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 592,593 | $17 | 592,593 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 592,593 | $17 | 5,554,094 | Form 4 |
Questions
What stock did Sr One Capital Management, LLC buy or sell?
Sr One Capital Management, LLC reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($27.2M) and 0 sales, across 1 company.
Is Sr One Capital Management, LLC the same person as other filers with this name?
This page covers SEC CIK 1853723 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Plain-text version for agents and LLMs: /insiders/sr-one-capital-management-llc-1853723.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.